Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Monday,Benzinga reports. The firm currently has a $18.00 target price on the stock. HC Wainwright also issued estimates for Coya Therapeutics’ Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.64) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Several other equities analysts also recently commented on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Up 1.2%

NASDAQ COYA opened at $4.20 on Monday. The stock has a market capitalization of $98.52 million, a PE ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a 12-month low of $3.94 and a 12-month high of $7.75. The company has a 50 day moving average price of $4.66 and a two-hundred day moving average price of $5.47.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. As a group, equities analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently bought and sold shares of the company. Prosperity Wealth Management Inc. grew its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics during the 3rd quarter worth about $28,000. CIBC Private Wealth Group LLC acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $47,000. Occudo Quantitative Strategies LP bought a new stake in Coya Therapeutics during the 4th quarter valued at approximately $66,000. Finally, Lantern Wealth Advisors LLC bought a new stake in Coya Therapeutics during the 3rd quarter valued at approximately $66,000. 39.75% of the stock is currently owned by institutional investors.

Trending Headlines about Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $18 price target on COYA, a signal of analyst conviction that can support investor demand. HC Wainwright Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)
• Positive Sentiment: HC Wainwright nudged its Q4 2026 estimate slightly higher (from ($0.46) to ($0.43) EPS), a modest improvement for late-2026 profitability expectations that could be viewed positively by investors.
• Neutral Sentiment: HC Wainwright published multi-year forecasts (Q1–Q4 2027 and FY2027 EPS of around ($1.66)); these longer-horizon projections provide context but are farther out and less likely to move the stock near term.
• Neutral Sentiment: Public short-interest postings in March show “0 shares” and NaN changes — an apparent data/reporting anomaly. That reduces the usefulness of the short-interest signal for explaining price moves today.
• Negative Sentiment: HC Wainwright cut several near-term 2026 EPS forecasts: Q1 (to ($0.39) from ($0.33)), Q2 (to ($0.39) from ($0.33)), Q3 (to ($0.41) from ($0.40)) and lowered FY2026 to ($1.64) from ($1.52). These downgrades reflect weaker near-term profitability expectations and likely weigh on sentiment.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.